Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: A multicenter study

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Miao, Weibing ^a   Zheng, Shan ^a   Dai, Haojie ^b   Wang, Feng ^c   Jin, Xiaona ^d   Zhu, Zhaohui ^d   Jia, Bing ^e  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN RECEPTOR; MEDRONATE TECHNETIUM TC 99M; PEGYLATED ARGININE GLYCINE ASPARTIC ACID TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; CYCLOPEPTIDE; TECHNETIUM 99M (HYNIC-3PRGD(2))(TRICINE)(TPPTS); TECHNETIUM COMPLEX;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LUNG CANCER; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; WHOLE BODY PET; AGED; BONE NEOPLASMS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SECONDARY; TIME;

AGED; BONE NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; TECHNETIUM TC 99M MEDRONATE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908360112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111221     Document Type: Article

References (30)

1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al.. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-14.
2. Higgins MJ, Ettinger DS (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther 9:1365-78.
3. Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, et al.. (2011) Imaging of lung cancer in the era of molecular medicine. Acad Radiol 18:424-36.
4. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
5. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alphav beta3 for angiogenesis. Science 264:569-71.
6. Ruoslahti e (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90.
7. Sengupta S, Chattopadhyay N, Mitra A, Ray S, Dasgupta S, et al.. (2001) Role of avb3 integrin receptors in breast tumor. J Exp Clin Cancer Res 20:585-90.
8. Zitzmann S, Ehemann V, Schwab M (2002) Arginine-Glycine-Aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res 62:5139-43.
9. Costouros NG, Diehn FE, Libutti SK (2002) Molecular imaging of tumor angiogenesis. J Cell Biochem (Suppl) 39:72-8.
10. Liu S, Robinson SP, Edwards DS (2005) Radiolabeled integrin avb3 antagonists as radiopharmaceuticals for tumor radiotherapy. Topics in Current Chem 252:117-53.
11. Haubner R, Wester HJ (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm des 10:1439-55.
12. Pasqualini R, Koivunen E, Ruoslahti e (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542-6.
13. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, et al.. (2005) Noninvasive visualization of the activated aVb3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD. PLOS Med 2:244-52.
14. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, et al.. (2001) Noninvasive imaging of avb3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Research 61:1781-5.
15. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, et al.. (2005) Biodistribution and pharmacokinetics of the avb3-selective tracer 18F-Galacto-RGD in cancer patients. J Nucl Med 46:1333-41.
16. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, et al.. (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin aVb3 expression in man. Clin Cancer Res 12:3942-9.
17. McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, et al.. (2008) The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 49:1664-7.
18. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, et al.. (2008) Phase I trial of the positron-emitting Arg-Gly-Asp peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49:879-86.
19. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, et al.. (2006) Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 47:1434-9.
20. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ; Study Group (2010) An open-label, multi-center, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the aVb3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol 51:40-6.
21. Liu Z, Niu G, Shi J, Liu S, Wang F, et al.. (2009) (68) Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 36:947-57.
22. Liu Z, Liu S, Wang F, Liu S, Chen X (2009) Noninvasive imaging of tumor integrin expression using (18) F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging 36:1296-307.
23. Shi J, Wang L, Kim YS, Zhai S, Jia B, et al.. (2009) 99mTcO (MAG2-3G3-dimer): a new integrin alpha (v) beta (3) - targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging 36:1874-84.
24. Wang L, Shi J, Kim YS, Zhai S, Jia B, et al.. (2009) Improving tumor-targeting capability and pharmacokinetics of (99m) Tc-labeled cyclic RGD dimers with PEG (4) linkers. Mol Pharm 6:231-45.
25. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, et al.. (2009) 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjugate Chem 20:1559-68.
26. Liu Z, Jia B, Shi J, Jin X, Zhao H, et al.. (2010) Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin aVb3 expressed on both tumor cells and neovasculature. Bioconjug Chem 21:548-55.
27. Jia B, Liu Z, Zhu Z, Shi J, Jin X, et al.. (2011) Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin aVb3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol 13:730-6.
28. Zhu Z, Miao W, Li Q, Dai H, Ma Q, et al.. (2012) 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multi-center study. J Nucl Med 53:716-22.
29. Pichler BJ, Kneilling M, Haubner R, Braumüller H, Schwaiger M, et al.. (2005) Imaging of delayed-type hypersensitivity reaction by PET and 18FGalacto-RGD. J Nucl Med 46:184-9.
30. McDonald DM, Choyke PL (2003) Imaging of angiogenesis: From microscope to clinic. Nature Medicine 9:713-25.